BioSpace News Archive

Addex Therapeutics Ltd, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it has extended its research collaboration agreement with Indivior PLC.

We regained the momentum in Monjuvi sales as we exited the second quarter and are encouraged to see that momentum continuing into Q3,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced its half year 2021 financial results and provided a second quarter business update and outlook for the remainder of the year.

Karen Linehan and Philippe Luscan, who have led Legal, Ethics & Business Integrity and Industrial Affairs at Sanofi for the last 14 and 13 years respectively have decided to retire.

Ipsen, a global specialty-driven biopharmaceutical company, announced its financial results for the first half of 2021:

Ear infection is the second most common condition in dogs. Depending on the part of ear, it can be of three types: otitis externa, otitis media, and otitis interna.

Combi-chem and throughput screenings allow creation of several new materials in shortest possible time by using automation to their advantage.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, announced the expansion of the company’s board of directors with key appointments, including:

Everest Medicines announced that the Taiwan Food and Drug Administration has granted Pediatric and Rare Severe Disease Priority Review Designation for sacituzumab govitecan-hziy, an investigational treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Merck, known as MSD outside the United States and Canada, announced financial results for the second quarter of 2021.